SCHEMBL6086385

SCHEMBL6086385

Cc1cc(CNC(=O)c2nc(N3CCCC4(CCOCC4)C3)n(C)c(=O)c2O)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 6/20 0.39
KCNE1 P15382 1/20 0.39
CCR1 P32246 1/20 0.39
KCNQ1 P51787 1/20 0.39
KCNH2 Q12809 1/20 0.37
CYP2C9 P11712 1/20 0.37
MMP10 P09238 2/20 0.36
MMP8 P22894 2/20 0.36
MYC P01106 2/20 0.36
WDR5 P61964 2/20 0.36
DRD3 P35462 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
PPARG P37231 1/20 0.35
PDE5A O76074 1/20 0.35
MAPT P10636 2/20 0.34
PIK3CD O00329 1/20 0.34
CYP3A4 P08684 1/20 0.34
AKT1 P31749 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087546 0.92 MMP13 (0.42) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6087374 0.88 MMP13 (0.43) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6095011 0.88 MMP13 (0.44) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6093967 0.87 MMP13 (0.47) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6088926 0.86 KCNE1 (0.45) KCNE1CCR1KCNQ1KCNH2CYP2C9
SCHEMBL6088176 0.84 KCNH2 (0.48) KCNE1CCR1KCNQ1KCNH2CYP2C9
SCHEMBL5309519 0.84 MAPK8 (0.42) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6088750 0.84 MMP13 (0.38) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6089345 0.83 MMP13 (0.39) MMP13KCNE1CCR1KCNQ1KCNH2
SCHEMBL6094684 0.83 MMP13 (0.41) MMP13KCNE1CCR1KCNQ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115601-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-10-03 US claimed
US-20050261322-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-11-24 US claimed
US-7115601-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-10-03 US disclosed
US-20050261322-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261322-A1 HIV integrase inhibitors TYMP, PAICS, TYMS MMP13 4089/4885KCNE1 3346/4885CCR1 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.